ISCO — International Stem Cell Share Price
Last trade - 00:00- $0.58m
- $2.69m
- $7.79m
- 53
- 65
- 13
- 39
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 20.79 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 1.44 | ||
| Price to Sales | 0.08 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -209.18% | ||
| Return on Equity | n/a | ||
| Operating Margin | -10.76% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 9.47 | 7.13 | 7.18 | 8.18 | 7.79 | n/a | n/a | -6.82% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
International Stem Cell Corporation is a clinical-stage biotechnology company that is focused on therapeutic and biomedical product development. The Company is primarily a research and development company, for the therapeutic market, which has focused on advancing potential clinical applications of human parthenogenetic stem cells (hpSCs) for the treatment of various diseases of the central nervous system and liver diseases. The Company's products are based on human cell culture and a type of pluripotent stem cells and hpSCs. The Company's subsidiaries include Lifeline Cell Technology, LLC (LCT), which develops, manufactures and commercializes primary human cell research products for the biomedical market; Lifeline Skin Care, Inc. (LSC), which develops, manufactures and markets a category of anti-aging skin care products for anti-aging market, and Cyto Therapeutics Pty. Ltd. (Cyto Therapeutics) performs research and development (R&D) for the therapeutic market.
Directors
- Andrey Semechkin CCH (61)
- Donald Wright CCH (73)
- Russell Kern EVP (35)
- Sophia Garnette VOP (37)
- Paul Maier IND (73)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- June 7th, 2005
- Public Since
- September 25th, 2006
- No. of Shareholders
- 632
- No. of Employees
- 29
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 8,004,389
- Address
- 5950 Priestly Dr, CARLSBAD, 92008-8849
- Web
- https://www.internationalstemcell.com/
- Phone
- +1 7609406383
- Auditors
- BDO USA, LLP
Upcoming Events for ISCO
Similar to ISCO
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
As of Today at 21:22 UTC, shares in International Stem Cell are trading at $0.08. This share price information is delayed by 15 minutes.
Shares in International Stem Cell last closed at $0.08 and the price had moved by -42.5% over the past 365 days. In terms of relative price strength the International Stem Cell share price has underperformed the S&P500 Index by -51.74% over the past year.
There is no consensus recommendation for this security.
International Stem Cell does not currently pay a dividend.
International Stem Cell does not currently pay a dividend.
International Stem Cell does not currently pay a dividend.
To buy shares in International Stem Cell you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.08, shares in International Stem Cell had a market capitalisation of $0.64m.
Here are the trading details for International Stem Cell:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ISCO
Based on an overall assessment of its quality, value and momentum International Stem Cell is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like International Stem Cell. Over the past six months, its share price has underperformed the S&P500 Index by -27.1%.
As of the last closing price of $0.08, shares in International Stem Cell were trading -33.85% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The International Stem Cell PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.08.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
International Stem Cell's management team is headed by:
- Andrey Semechkin - CCH
- Donald Wright - CCH
- Russell Kern - EVP
- Sophia Garnette - VOP
- Paul Maier - IND